Sharon Hesterlee

Drug improves insulin sensitivity but not other aspects of MMD1

posted on June 29, 2009 - 2:52pm
The drug Iplex, developed by the Richmond, Va., biopharmaceutical company Insmed, did not improve muscle function, strength or endurance in a phase 2 trial in type 1 myotonic dystrophy (MMD1, or DM1), the company announced June 25, 2009. (See Insmed Announces Results.)

New content is being added every day. Please check back again.